
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc is making significant strides in the development of precision medicines for chronic kidney disease (CKD), particularly with its lead programs MZE829 and MZE782, which have demonstrated compelling efficacy signals in clinical trials. The expected enhancement of the commercial landscape due to improved ICD-10-CM codes, combined with the positive trends in proteinuria reduction and eGFR slope from MZE829's Phase 2 HORIZON trial, supports the likelihood of accelerated regulatory approval. Additionally, the promising pharmacokinetic profile of MZE782, along with its strong efficacy data, positions Maze competitively in the market and justifies an increased projection for market penetration of MZE829, signaling a favorable outlook for the company's stock.
Bears say
Maze Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock performance. The company is advancing investigational drugs for chronic kidney disease (CKD) but is encountering difficulties in demonstrating robust efficacy signals, with risks related to variable patient responses and concerns about the reliability of surrogate endpoints, which may hinder progress in clinical trials. Additionally, the observed dose-dependent declines in estimated glomerular filtration rate (eGFR) among patients, coupled with the substantial proportion of individuals experiencing inadequate responses to existing treatments, raises concerns about the commercial viability and therapeutic impact of Maze Therapeutics's pipeline products.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares